regulator in Biological Technology
Navigation Links
regulator in Biological Technology
... demonstrated to improve cystic
fibrosis transmembrane conductance regulator (CFTR) protein functionality.
BioMarin expects the lead compounds to ... caused by mutations
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
With an incidence of approximately 1/3,500 births, cystic ...
... metabolite" that targets multiple pathways of cellular stress and myocardial injury to counter net ATP catabolism and, as such, acts as a key regulator of cellular energetics. Endogenous adenosine protects cells from multiple pathways of injury such as inflammation, apoptosis and necrosis. Endogenous ...
... via electronic case report forms (eCRFs), and enables productive clinical trials management. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulator guidelines and is designed as a lightweight, standards-based, extensible, and modular platform. All versions of OpenClinica are available for free ...
... for MedImmune's eight research posters to be presented at the meeting, starting on Sunday October 26, is as follows: -- ICOS as a potential regulator in inclusion body myositis and dermatomyositis - Chris Morehouse, M.Sc., Sunday, October 26 from 9:00 a.m. - 11:00 a.m. in Hall A, ...
... inherited, and sometimes fatal metabolic bone disease. Patients have low levels of the tissue non-specific form of alkaline phosphatase, an important regulator of bone mineralization, leading to rickets in infants and children and osteomalacia ("soft bones" resulting from poor mineralization) in adults. ...
... http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) Patients with CF lack adequate levels of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride channel which is required for normal function of the lung, pancreas, liver, and other organs. Nonsense mutations are ...
... to hamper our progress." Addrenex's goal is to develop a diverse pipeline of products aimed at regulating the adrenergic system, a vast and varied regulator of multiple bodily processes. The alpha-2 adrenergic receptors in particular have been implicated in a wide variety of medical conditions, including ...
Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
... Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone). Denosumab is being investigated for its potential to inhibit all stages of osteoclast activity ...... metabolite" that targets multiple pathways of cellular stress and myocardial injury to counter net ATP catabolism and, as such, acts as a key regulator of cellular energetics. Endogenous adenosine protects cells from multiple pathways of injury such as inflammation, apoptosis and necrosis. Endogenous ...
MIT reels in RNA surprise with microbial ocean catch
... samples, she found that much of the novel RNA they expected to be protein-coding was actually small RNA (or sRNA), which can serve as a catalyst or regulator for metabolic pathways in microbes. "What's surprising to me is the abundance of novel sRNA candidates in our data sets," said Shi. "When I looked ...EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
... currently in Phase 1 studies in advanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently ...Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
... mechanism of action of AF is believed to be that treatment with AF results in translocation of the arylhydrocarbon receptor (AhR; a transcriptional regulator of CYP1A1) from the cytoplasm to the nucleus, and its subsequent interaction with the xenobiotic-response element (XRE) sequence on the CYP1A1 ...Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
... and pharmacodynamic data VANCOUVER, April 28 /PRNewswire/ - Inimex Pharmaceuticals is pleased to announce that its novel Innate Defense regulator (IDR) IMX942 was administered to human subjects for the first time on April 27, 2009. The healthy volunteers were enrolled in a Phase 1 safety study ...Beyond associations: Colorectal cancer culprit found
... consequences of this SNP. The group found that the SNP causes the expression of a nearby gene, called SMAD7 , to decrease. SMAD7 is an inhibitory regulator of TGF-beta signaling. If cellular levels of SMAD7 are down, critical signaling events could be set into motion, leading the cell on the path to ...Akaza Research to Present OpenClinica at ACRP Global Conference & Exhibition
... via electronic case report forms (eCRFs), and enables productive clinical trials management. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulator guidelines and is designed as a lightweight, standards-based, extensible, and modular platform. All versions of OpenClinica are available for free ...Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
... and sometimes fatal metabolic bone disease. Affected patients have low levels of the tissue non-specific form of alkaline phosphatase, an essential regulator of bone mineralization, leading to rickets in infants and children and osteomalacia ("soft bones" resulting from poor mineralization) in adults. ...FDA Accepts Amgen's Submission and Files Biologics License Application for Denosumab
... Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone). Denosumab is being investigated for its potential to inhibit all stages of osteoclast activity ...Registration Open for OpenClinica European Summit - April 14, 2009
... via electronic case report forms (eCRFs), and enables productive clinical trials management. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulator guidelines and is designed as a lightweight, standards-based, extensible, and modular platform. All versions of OpenClinica are available for free ...... via electronic case report forms (eCRFs), and enables productive clinical trials management. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulator guidelines and is designed as a lightweight, standards-based, extensible, and modular platform. All versions of OpenClinica are available for free ...
EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
... pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase ...EntreMed to Present at the New York Society of Security Analysts Industry Conference
... pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase ...EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
... pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase ...EntreMed Reports Third Quarter 2008 Financial Results
... pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase ...AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO
... authority on Chinese joint venture and wholly foreign owned enterprise (WFOE) structuring and considered an expert on the China government and regulator and compliance system. Among his other accomplishments, Mr. MacLellan also brings over twenty years of active board experience to AMDL. With more ...Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models
... pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ...... for MedImmune's eight research posters to be presented at the meeting, starting on Sunday October 26, is as follows: -- ICOS as a potential regulator in inclusion body myositis and dermatomyositis - Chris Morehouse, M.Sc., Sunday, October 26 from 9:00 a.m. - 11:00 a.m. in Hall A, ...
EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
... pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ...EntreMed to Present at BioPartnering Europe Conference
... pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ...EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
... pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ...... inherited, and sometimes fatal metabolic bone disease. Patients have low levels of the tissue non-specific form of alkaline phosphatase, an important regulator of bone mineralization, leading to rickets in infants and children and osteomalacia ("soft bones" resulting from poor mineralization) in adults. ...
... http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) Patients with CF lack adequate levels of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride channel which is required for normal function of the lung, pancreas, liver, and other organs. Nonsense mutations are ...
EntreMed Reports Second Quarter 2008 Financial Results
... for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in ...Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
... indications that we plan to investigate with NU206." About NU206 NU206 (R-spondin1) is a recombinant, secreted protein that acts as a key regulator of the Wnt pathway, the critical pathway that stimulates cell growth and differentiation during homeostasis and pathogenesis in specific tissues ...EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
... for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in ...Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
... for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in ...JCI table of contents: April 22, 2008
... stewart.keith@mayo.edu . View the PDF of this article at: https://www.the-jci.org/article.php?id=34149 REPRODUCTIVE BIOLOGY: How is a regulator of sex hormone production regulated itself? The production of the sex hormones testosterone, progesterone, and estrogen is controlled by two ...EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
... for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in ...Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
... and has an excellent therapeutic window due to its low toxicity. The mode of action of LOR-253 involves the downregulation of cyclin D1, an important regulator of cell cycle progression and cell proliferation, and induction of the tumor suppressor Kruppel like factor 4 (KLF-4). Alterations in KLF-4 ...Paloma Pharmaceuticals to Present at the American Association for Cancer Research
... to transmit its signal through the cell as well as inhibiting the synthesis of pro-angiogenic factors through inhibition of HIF-1(alpha), a known regulator of the synthesis of pro-angiogenic cytokines by tumor cells. As P529 is shown to inhibit all tumor cell lines of the National Cancer Institute's 60 ...EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
... for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in ...EntreMed Receives Nasdaq Deficiency Notice
... for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study in advanced cancer patients and ENMD-2076, a ...EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
... for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, is in a Phase 1 study in advanced cancer patients, and ENMD-2076, a ...EntreMed Announces 2008 Corporate and Clinical Program Priorities
... for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. The Company has approved ...EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
... for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ...... to hamper our progress." Addrenex's goal is to develop a diverse pipeline of products aimed at regulating the adrenergic system, a vast and varied regulator of multiple bodily processes. The alpha-2 adrenergic receptors in particular have been implicated in a wide variety of medical conditions, including ...
EntreMed to Present at BIO CEO and Investor Conference
... for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ...Other ContentsbronchitisbronchitisbronchitisbronchoscopybronchoscopybronchiolitisbronchiolitisbrucellosisbruisesbruisesbubonicbubonicbubonicrecluseOther TagsLakhStimulatorundergoesjointly
(Date:11/26/2009)...2009) Whitehead researchers have developed a new ... specific genes and proteins used by pathogens, ac...uman cell cultures genes are present in two copies...other. Gene inactivation by mutation is therefore ...the second copy usually remains active and takes o...
(Date:11/26/2009)...aphylococcus Aureus ) and other drug-resistant bac...lasma prototype devices have been developed to off...cktails. , Two prototype devices have been devel...in (e.g. hands and feet) in hospitals and public s... another to shoot bacteria-killing agents into inf...
(Date:11/25/2009)...the stomach, may be used to boost resistance to, o...le School of Medicine researchers report in a stud...euroscience . , Parkinson,s disease is caused by...the midbrain known as the substantia nigra, which ...roduction of dopamine in late-stage Parkinson,s ca...
Breaking Biology News(10 mins):Knockouts in human cells point to pathogenic targets 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Hormone ghrelin can boost resistance to Parkinson's disease 2Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 1Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 2Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 3Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 4Purple Communications Invites Greater San Ramon Community to Celebrate Ms Ella Mae Lentz Finalist in Dream Bigger Initiative 54878 5Collexis BiomedExperts com Achieves 200 000 Registered Users 54873 1Collexis BiomedExperts com Achieves 200 000 Registered Users 54873 2Collexis BiomedExperts com Achieves 200 000 Registered Users 54873 3Eclipsemed Ltd to Introduce EndyMed PRO 28TM 29 to U S Aesthetic Market 54868 1Eclipsemed Ltd to Introduce EndyMed PRO 28TM 29 to U S Aesthetic Market 54868 2Eclipsemed Ltd to Introduce EndyMed PRO 28TM 29 to U S Aesthetic Market 54868 3(Date:11/30/2009)... SILVER SPRING, Md., Nov. 30 /PRNewswire-USNewswir...a bronzed body year-round, but the ultraviolet (UV...h risks. ,, (Logo: http://www.newscom.com/cgi... people think that a tan gives them a ,healthy, gl... Miller, M.S.E.E., a Food and Drug Administration ...
(Date:11/30/2009)...O, Nov. 30 Physicians at Beth Isra...y on results of a study demonstrating the potentia...y (cCTA) by Rcadia,s COR Analyzer System® to ...sis in hospital emergency department (ED ) patient...stem to enhance the use of cCTA has potential to s...
(Date:11/30/2009)...f Navarra Hospital has launched a series of clinic...munotherapy treatment. This approach involves the ... healthy and tumour cells from the patient him or ...of the most aggressive and frequent malignant tumo...ing patients combined with the standard, first-lin...
(Date:11/30/2009)... Peter J. Rappa, MD, explores the intricate...ew book "Healing Heart to Soul: One Doctor&rs...Brown Books 2009). , Dall...and refusing to let go of negative emotions, wheth...heavy on our shoulders. Oftentimes, this disease o...
(Date:11/30/2009)... NEW YORK, Nov. 30 Reportlinker.co...vailable in its catalogue: ,, Gene Therapy - W..., http://www.reportlinker.com/p0164218/Gene-The...html ,, Gene therapy promises to be one of th...o significant achievements for curing disease have...
Breaking Medicine News(10 mins):Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 2Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 3Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 4Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 5Health News:Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines 6Health News:Healing from the Inside Out: Compelling New Book Explores the Intricate Connection between Body, Soul, and Better Health 2Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 2Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 3Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 4Health News:Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities 5[0] Indoor Tanning: The Risks of Ultraviolet Rays[0] Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease[0] Clinical trials launched for treating most aggressive brain tumor with personalized cell vaccines[0] Healing from the Inside Out: Compelling New Book Explores the Intricate Connection between Body, Soul, and Better Health[0] Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities
EncephalopathyPlectasinLakhSteadilyPolymicrobialStimulatorNanobombsMinimizedFleaundergoesUncleanjointlysharpernonalcoholic
Other Tagstesting 2testing 3testing 4testing 5testing 6testing 7testing 8testing 9testing 10cleared 2cleared 3cleared 4cleared 5cleared 6cleared 7designed 2designed 3designed 4designed 5designed 6designed 7designed 8designed 9designed 10first 2first 3first 4first 5first 6first 7first 8first 9first 10stroke 2stroke 3stroke 4stroke 5stroke 6stroke 7stroke 8stroke 9stroke 10positive 2positive 3positive 4positive 5positive 6positive 7positive 8positive 9positive 10
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |